Joaquin Rodrigo, General Manager – Sandoz Iberia
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz was a company that merged with Ciba-Geigy to form Novartis. The name was later reused as the name of Novartis’ generic drug subsidiary.
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential…
Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis. The US…
Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country.…
Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies…
Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration…
Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio…
Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing…
The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
Mr. Willis, you have a background as a management consultant in New Zealand and Australia. What was the situation of the generics market when you arrived in the Philippines and…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
See our Cookie Privacy Policy Here
